Not for release to US wire services or distribution in the United States MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 2 February 2024:  Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that its Securities Purchase Plan (SPP) has been ...

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 29 January 2024:  Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will participate in the ShareCafe Hidden Gems webinar on the following dates/times: AUSTRALIA PARTICIPANTS: ...

Highlights MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 31 January 2024, Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31 December 2023 (Q2 ...

EGM Presentation 2023

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 4 December 2023:  Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, will be hosting an investor webcast on Wednesday, 6 December 2023 in Australia / Tuesday, 5 December 2023 in the United States. Details ...

– ATH434 improved motor performance and general function – – Webcast to be held this week to discuss new data and recent clinical progress – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 4 December 2023:  Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for ...

Good morning all and thank you for joining us today. I’m pleased to share with you my chairman’s address for our FY23 Annual General Meeting for Alterity Therapeutics. We are hosting this meeting both in person in Melbourne and virtually, to ensure all of our shareholders, employees and corporate partners are able to join us. ...

AGM 2023 Presentation

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 27 November 2023:  Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced a poster presentation from the Company’s Biomarkers of progression in Multiple System Atrophy (bioMUSE) Natural History Study at the recent 34th ...